Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy
Authors:
- Daniel J. SerieDSDaniel J. Serie
- Julia E. CrookJCJulia E. Crook
- Brian M. NecelaBNBrian M. Necela
- Bianca C. AxenfeldBABianca C. Axenfeld
- Travis J. DockterTDTravis J. Dockter
- Gerardo Colon-OteroGCGerardo Colon-Otero
- Edith A. PerezEPEdith A. Perez
- E. Aubrey ThompsonETE. Aubrey Thompson
- Nadine NortonNNNadine Norton
Open Access
- 4 May 2017
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 4 (2) , 6
Abstract
Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer. In mouse models, doxorubicin is known to cause cardiomyopathy and conditional cardiac knock out of Erbb2 results in dilated cardiomyopathy and increased sensitivity to doxorubicin-induced cell death. In humans, these drugs also result in cardiac phenotypes, but severity and reversibility is highly variable. We examined the association of decline in left ventricular ejection fraction (LVEF) at 15,204 single nucleotide polymorphisms (SNPs) spanning 72 cardiomyopathy genes, in 800 breast cancer patients who received doxorubicin and trastuzumab. For 7033 common SNPs (minor allele frequency (MAF) > 0.01) we performed single marker linear regression. For all SNPs, we performed gene-based testing with SNP-set (Sequence) Kernel Association Tests: SKAT, SKAT-O and SKAT-common/rare under rare variant non-burden; rare variant optimized burden and non-burden tests; and a combination of rare and common variants respectively. Single marker analyses identified seven missense variants in OBSCN (p = 0.0045–0.0009, MAF = 0.18–0.50) and two in TTN (both p = 0.04, MAF = 0.22). Gene-based rare variant analyses, SKAT and SKAT-O, performed very similarly (ILK, TCAP, DSC2, VCL, FXN, DSP and KCNQ1, p = 0.042–0.006). Gene-based tests of rare/common variants were significant at the nominal 5% level for OBSCN as well as TCAP, DSC2, VCL, NEXN, KCNJ2 and DMD (p = 0.044–0.008). Our results suggest that rare and common variants in OBSCN, as well as in other genes, could have modifying effects in cardiomyopathy.Keywords
This publication has 25 references indexed in Scilit:
- Dilated cardiomyopathy: the complexity of a diverse genetic architectureNature Reviews Cardiology, 2013
- Optimal Unified Approach for Rare-Variant Association Testing with Application to Small-Sample Case-Control Whole-Exome Sequencing StudiesThe American Journal of Human Genetics, 2012
- Evaluating Pathogenicity of Rare Variants From Dilated Cardiomyopathy in the Exome EraCirculation: Cardiovascular Genetics, 2012
- Truncations of Titin Causing Dilated CardiomyopathyNew England Journal of Medicine, 2012
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- Rare-Variant Association Testing for Sequencing Data with the Sequence Kernel Association TestThe American Journal of Human Genetics, 2011
- A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathyEuropean Heart Journal, 2011
- Genome-wide Studies of Copy Number Variation and Exome Sequencing Identify Rare Variants in BAG3 as a Cause of Dilated CardiomyopathyThe American Journal of Human Genetics, 2011
- Coding Sequence Rare Variants Identified in MYBPC3 , MYH6 , TPM1 , TNNC1 , and TNNI3 From 312 Patients With Familial or Idiopathic Dilated CardiomyopathyCirculation: Cardiovascular Genetics, 2010
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001